UBS/CALL/MODERNA/180.001/0.1/21.03.25 | Market Closed - Swiss Exchange 16:20:00 21/06/2024 BST | ||
| 1.12 CHF | -4.27% |
|
| Current month | -32.93% | ||
| 1 month | -14.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 1.12 | -4.27% |
| 20/06/24 | 1.17 | +12.50% |
| 19/06/24 | 1.04 | -1.89% |
| 18/06/24 | 1.06 | -13.82% |
| 17/06/24 | 1.23 | -9.56% |
Delayed Quote Swiss Exchange
Last update June 21, 2024 at 04:20 pm
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| 9DUBSU | |
| ISIN | CH1344027664 |
| Date issued | 06/05/2024 |
| Strike | 180 $ |
| Maturity | 21/03/2025 (272 Days) |
| Parity | 10 : 1 |
| Emission price | 0.85 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.69 CHF |
|---|---|
| Lowest since issue | 0.69 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.89% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.4
USD
Average target price
145.9
USD
Spread / Average Target
+9.34%
- Stock Market
- Warrants
- 9DUBSU Warrant
